Skip to main content
Mendus logo

Mendus — Investor Relations & Filings

Ticker · IMMU ISIN · SE0005003654 LEI · 529900AFBGFR7ZB50J95 ST Manufacturing
Open in API
Filings indexed 407 across all filing types
Latest filing 2026-05-08 AGM Information
Country SE Sweden
Listing ST IMMU

About Mendus

https://mendus.com/

Mendus is a clinical-stage company developing immunotherapies to improve long-term survival for cancer patients. The company's primary focus is on preventing tumor recurrence, a leading cause of cancer-related mortality. By leveraging its expertise in allogeneic dendritic cell biology, Mendus designs therapies that stimulate the immune system to build active and long-lasting immunity against residual cancer cells. This approach aims to change the course of cancer treatment by offering durable responses while preserving the patient's quality of life. The company's pipeline is centered on maintenance therapies for various forms of cancer.

Recent filings

Filing Released Lang Actions
Report from the Annual General Meeting of Mendus AB (publ) on 8 May 2026
AGM Information Classification · 100% confidence The document is a detailed press release reporting on the resolutions and outcomes of the Annual General Meeting (AGM) of Mendus AB held on 8 May 2026. It includes adoption of financial statements, board member elections, remuneration decisions, share issuance authorizations, and incentive program approvals. The content is focused on the AGM proceedings and decisions rather than presenting a full annual report or financial statements themselves. The document explicitly references the AGM and its resolutions multiple times, and it is not a brief announcement or a certification. Therefore, the document fits the category of AGM Information (AGM-R).
2026-05-08 English
Kommuniké från årsstämma i Mendus AB (publ) den 8 maj 2026
AGM Information Classification · 95% confidence The document is a press release dated May 8, 2026, reporting on the decisions made at the Annual General Meeting (Årsstämma) of Mendus AB. It includes details such as approval of financial statements, discharge of liability for the board and CEO, approval of the remuneration report, election and re-election of board members and auditors, decisions on board and auditor fees, authorization for share issuance and share transfers, and approval of a long-term incentive program. The content is typical of AGM minutes or a summary of AGM decisions rather than the full annual report or financial statements themselves. The document is about the meeting outcomes and resolutions passed at the AGM, not the full report or detailed financial data. Therefore, it fits the category of AGM Information (AGM-R). The document length (9293 characters) is consistent with a detailed AGM summary but not a full annual report. Hence, the classification is AGM Information (AGM-R) with high confidence.
2026-05-08 English
Interim / Quarterly Report 2026
Interim / Quarterly Report Classification · 95% confidence The document is titled "Första kvartalsrapporten 2026" which translates to "First Quarterly Report 2026". It contains detailed financial data for the period January to March 2026, including net sales, results, earnings per share, cash, equity, and number of employees. It also includes a CEO statement, detailed descriptions of clinical programs, pipeline updates, and other operational information. The length is about 15,000 characters, indicating a full report rather than a brief announcement. The content and structure clearly indicate this is a comprehensive quarterly financial and operational report for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2026
2026-05-08 English
Interim / Quarterly Report 2026
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Report on the first quarter 2026' and contains detailed financial data for the period January to March 2026, including net sales, results, earnings per share, cash, shareholders equity, and number of employees. It also includes a CEO comment, significant events during and after the reporting period, and detailed descriptions of clinical trials and company strategy. The content is comprehensive and covers financial performance and business developments for a quarter, which aligns with an Interim / Quarterly Report. The document length is about 15,000 characters, indicating it is a full report rather than a brief announcement or summary. There is no indication that this is an announcement of a report or a certification letter. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2026
2026-05-08 English
Annual Report 2025
Annual Report Classification · 100% confidence The document is titled 'Års- och koncernredovisning 2025' (Annual and Consolidated Report 2025) for the company Mendus. It contains comprehensive financial information, including the Board of Directors' report, financial statements (income statement, balance sheet, cash flow), notes, and an auditor's report. It covers the full fiscal year 2025 and provides detailed business descriptions and financial summaries, which aligns perfectly with the definition of an Annual Report (10-K). FY 2025
2026-04-17 Swedish
Notice of Annual General Meeting in Mendus AB (publ)
Proxy Solicitation & Information Statement Classification · 92% confidence The document is a notice convening the Annual General Meeting, including the agenda, proxy instructions, and Nomination Committee proposals. It is sent to shareholders to inform them and solicit their votes. This matches the definition of a Proxy Solicitation & Information Statement (PSI).
2026-04-01 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.